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DOI 10.1016/j.ccr.2011.06.009SUMMARYMislocated enzymatic activity of DOT1L has been proposed as a driver of leukemogenesis in mixed lineage
leukemia (MLL). The characterization of EPZ004777, a potent, selective inhibitor of DOT1L is reported. Treat-
ment of MLL cells with the compound selectively inhibits H3K79 methylation and blocks expression of leuke-
mogenic genes. Exposure of leukemic cells to EPZ004777 results in selective killing of those cells bearing the
MLL gene translocation, with little effect on non-MLL-translocated cells. Finally, in vivo administration of
EPZ004777 leads to extension of survival in amouseMLL xenograft model. These results provide compelling
support for DOT1L inhibition as a basis for targeted therapeutics against MLL.INTRODUCTION
Mixed lineage leukemia (MLL) is a genetically distinct form of
acute leukemia that constitutes over 70% of infant leukemias
and approximately 10% of adult acute myeloid leukemias
(AML) (Hess, 2004; Krivtsov and Armstrong, 2007). MLL repre-
sents a particularly aggressive form of leukemia. Patients with
this disease generally have poor prognoses and often suffer
from early relapse after treatment with current therapies. There
is thus a great and present need for new treatment modalities
for patients suffering with MLL.
A universal hallmark of MLL disease is a chromosomal trans-
location affecting the MLL gene on chromosome 11q23 (Hess,
2004; Krivtsov and Armstrong, 2007). Normally, the MLL gene
encodes for a SET domain histone methyltransferase that
catalyzes the methylation of lysine 4 of histone H3 (H3K4) at
specific gene loci (Milne et al., 2002; Nakamura et al., 2002).Significance
In mixed lineage leukemia (MLL), chromosomal translocations
gene locations. This causes ectopic histone H3, lysine 79 (H3K
in leukemogenesis. DOT1L has thus been proposed as a pote
ment of EPZ004777, a potent, selective inhibitor of DOT1L. The
mogenic gene expression, and selectively kills cultured cel
EPZ004777 has antitumor activity in a mouse MLL xenograft
the goal of targeted therapeutics for MLL patients.Gene localization is conferred by specific interactions with
recognition elements within MLL, external to the SET domain
(Ayton et al., 2004; Slany et al., 1998; Zeleznik-Le et al.,
1994). In the disease-linked translocations, the catalytic SET
domain is lost and the remaining MLL protein is fused to
a variety of partners, including members of the AF and ENL
family of proteins such as AF4, AF9, AF10, and ENL (Hess,
2004; Krivtsov and Armstrong, 2007; Slany, 2009). These fusion
partners are capable of interacting directly, or indirectly, with
another histone methyltransferase, DOT1L (Bitoun et al.,
2007; Mohan et al., 2010; Mueller et al., 2007, 2009; Okada
et al., 2005; Park et al., 2010; Yokoyama et al., 2010; Zhang
et al., 2006). As a result, translocation products retain gene-
specific recognition elements within the remainder of the MLL
protein, but also gain the ability to recruit DOT1L to these loca-
tions (Monroe et al., 2010; Mueller et al., 2007, 2009; Okada
et al., 2005).of the MLL gene result in recruitment of DOT1L to aberrant
79) methylation, and increased expression of genes involved
ntial therapeutic target in MLL. Here, we report the develop-
compound blocks cellular H3K79methylation, inhibits leuke-
ls bearing MLL translocations. In addition, we show that
model. This work represents a significant advance toward
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Figure 1. Biochemical Characterization of
EPZ004777 Inhibition of DOT1L
(A) Chemical structure of EPZ004777.
(B) Inhibition of recombinant human DOT1L by
EPZ004777. Each data point represents the mean of two
replicates at each specified concentration of compound.
The data are fit to a standard Langmuir isotherm equation
for inhibition (Copeland, 2005).
(C) Plot of IC50 values of EPZ004777 as a function of SAM
concentration relative to the Km of S-adenosylmethionine
(SAM) ([SAM]/Km). These values display a linear relation-
ship as expected for SAM-competitive inhibition with a Ki
of 0.3 ± 0.03 nM (± error represents standard error of the
mean [SEM]).
(D) Plot of IC50 values for EPZ004777 against a panel of
human HMT enzymes.
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fication associated with actively transcribed genes (Feng et al.,
2002; Steger et al., 2008). The ectopic H3K79 methylation that
results from MLL fusion protein recruitment of DOT1L leads to
enhanced expression of leukemogenic genes, including
HOXA9 and MEIS1 (Guenther et al., 2008; Krivtsov et al., 2008;
Milne et al., 2005; Monroe et al., 2010; Mueller et al., 2009;
Nguyen et al., 2011; Okada et al., 2005; Thiel et al., 2010). Hence,
while DOT1L is not genetically altered in the disease per se, its
mislocated enzymatic activity is a direct consequence of the
chromosomal translocation affecting MLL patients. Studies in
model systems have demonstrated that DOT1L is required for
the transforming activity of MLL fusion proteins and DOT1L
has therefore been proposed to be a catalytic driver of leukemo-
genesis in this disease (Chang et al., 2010; Jo et al., 2011; Krivt-
sov et al., 2008; Monroe et al., 2010; Mueller et al., 2007; Nguyen
et al., 2011; Okada et al., 2005; Yokoyama et al., 2010).
As briefly summarized above, there is evidence to suggest that
the enzymatic activity of DOT1L is critical to pathogenesis in
MLL. Therefore, it has been proposed that inhibition of DOT1L
may provide a pharmacologic basis for therapeutic intervention
in this disease. However, in the absence of selective DOT1L
inhibitors, it has not been possible to address this hypothesis
directly. Toward this ultimate goal, we report here the develop-
ment of a small-molecule inhibitor of DOT1L.
RESULTS
Identification and Biochemical Characterization
of EPZ004777, a Potent andSelective Inhibitor of DOT1L
Based on the chemical structures of the S-adenosylmethionine
(SAM) substrate and S-adenosylhomocysteine (SAH) product,
the reaction mechanism of DOT1L catalysis and the published
crystal structure of the DOT1L active site, medicinal chemistry
design tenets were established to facilitate mechanism-guided
inhibitor discovery; chemical analogs thus designed were
synthesized and tested as inhibitors of DOT1L enzymatic
activity. From these efforts, EPZ004777 (Figure 1A) was identi-
fied. This compound demonstrates potent, concentration-54 Cancer Cell 20, 53–65, July 12, 2011 ª2011 Elsevier Inc.dependent inhibition of DOT1L enzyme activity with an IC50 of
400 ± 100 pM, as illustrated in Figure 1B. The chemical structure
of this compound retains the nucleoside core of the SAM
substrate, and SAH product. As such it was designed to bind
to the enzyme within the SAM binding pocket. Steady-state
kinetic analysis confirms that the compound binds to the enzyme
competitively with SAM. For example, a distinguishing feature of
competitive inhibition is a linear increase in the apparent IC50 of
the compound as a function of substrate concentration;
EPZ004777 displays this pattern when assayed as a function
of SAM concentration relative to the KM of SAM (Figure 1C).
SAM is a common methyl group donator that is used by all
histone methyltransferases (HMTs). Despite the universality of
SAM utilization by HMTs, EPZ004777 displays remarkable
selectivity for inhibition of DOT1L over other HMTs, as summa-
rized in Table 1 and Figure 1D. Thus, the compound displays
a minimum selectivity of >1000-fold for DOT1L relative to all
HMTs that have been tested.
EPZ004777 Selectively Inhibits Cellular H3K79
Methylation
Having established that EPZ004777 is a potent and highly selec-
tive DOT1L inhibitor in biochemical assays, we next tested the
ability of EPZ004777 to inhibit DOT1L in cells by immunoblot
analysis of extracted histones using an antibody specific for di-
methylated H3K79 (H3K79me2). Treatment of human cell lines
derived from MLL-rearranged acute myeloid leukemia (AML)
(MOLM-13, MLL-AF9), MLL-rearranged biphenotypic leukemia
(MV4-11, MLL-AF4), or non-MLL-rearranged T cell acute
leukemia (Jurkat) with EPZ004777 led to a concentration-depen-
dent reduction in global H3K79me2 levels (Figure 2A, upper
panel). To understand the kinetics of EPZ004777-mediated
cellular H3K79me2 depletion, we performed a time course anal-
ysis in MV4-11 cells incubated with 3 mMEPZ004777, a concen-
tration sufficient for maximal cellular DOT1L inhibition (Figure 2A,
lower panel). A modest reduction in H3K79me2 levels was
apparent within 1 day of treatment, but full depletion took
4–5 days. There is no known histone demethylase enzyme
specific for H3K79, so the decline in methylation at this residue
Table 1. Inhibition of Human Histone Methyltransferases by
EPZ004777
Enzyme IC50 (nM)
a Fold Selectivityb
DOT1L 0.4 ± 0.1 1.0
CARM1 >50,000 >100,000
EHMT2 >50,000 >100,000
EZH1c >50,000 >100,000
EZH2c >50,000 >100,000
PRMT1 >50,000 >100,000
PRMT5 521 ± 137 1280
PRMT8 >50,000 >100,000
SETD7 >50,000 >100,000
WHSC1 >50,000 >100,000
a IC50 is the concentration of compound resulting in 50% inhibition of
enzyme activity. ± error represents the 95% confidence interval.
b Fold selectivity is relative to DOT1L, and is calculated as the ratio of the
IC50 for the enzyme under study over the IC50 for DOT1L.
cMeasured in the context of the PRC2 multiprotein complex.
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into chromatin of unmethylated H3 through histone turnover
and replacement.
We saw a persistent residual western blot signal with the anti-
H3K79me2 antibody, even at the highest EPZ004777 concentra-
tions, and with extended compound incubation periods (Figures
2A and 2B; data not shown). One possibility is that the residual
signal is background caused by a low level of cross-reactivity
of the antibody with other methylated residues on histone H3.
Histone H3K79me1 levels were also evaluated and found to be
reduced by EPZ004777 treatment (Figure 2B, top panel). We
were unable to evaluate H3K79me3 levels because commer-
cially available anti-H3K79me3 antibodies demonstrated strong
cross-reactivity with unrelated methyl marks (data not shown).
To assess the specificity of EPZ004777 inhibitory activity in
cells, we immunoblotted histones extracted from EPZ004777-
treated MV4-11 cells with a panel of methyl-lysine and methyl-
arginine residue specific antibodies. As shown in Figure 2B,
the only methyl marks affected by EPZ004777 treatment were
H3K79me1 and H3K79me2. Importantly, we saw no changes
in H4R3me2, a residue targeted by PRMT5, the only HMT, other
than DOT1L, for which EPZ004777 gave a biochemical IC50 of
less than 50 mM. Furthermore, EPZ004777 treatment did not
change the methylation state of residues targeted by PRDM
and SMYD family members (H3K9 and H3K4, respectively).
This is significant because we were unable to assess
EPZ004777’s ability to inhibit these HMTs directly due a lack of
robust biochemical assays. These data are consistent with
EPZ004777 being a highly specific DOT1L inhibitor in a cellular
context.
EPZ004777 Blocks MLL Fusion Target Gene Expression
We next tested whether EPZ004777 was able to inhibit expres-
sion of key MLL fusion target genes. HOXA9 andMEIS1 overex-
pression is a hallmark of MLL-rearranged leukemias (Armstrong
et al., 2002; Ferrando et al., 2003; Ross et al., 2003, 2004; Rozov-
skaia et al., 2001; Yeoh et al., 2002). Furthermore, both genes are
bound by MLL fusion proteins, hypermethylated at H3K79 anddownregulated by DOT1L depletion in MLL fusion-expressing
cells, including theMV4-11 cell line (Chang et al., 2010; Guenther
et al., 2008; Jo et al., 2011; Krivtsov et al., 2008; Lin et al., 2010;
Milne et al., 2005; Monroe et al., 2010; Mueller et al., 2009;
Nguyen et al., 2011; Okada et al., 2005; Thiel et al., 2010; Yo-
koyama et al., 2010). We used quantitative real-time PCR to
examine the effect of EPZ004777 on HOXA9 and MEIS1 tran-
script levels in MOLM-13 and MV4-11 cells (expression of these
transcripts in non-MLL-rearranged Jurkat cells was below the
limit of real-time PCR quantitation). Treatment with EPZ004777
led to a concentration-dependent decrease of both transcripts
in each cell line with IC50s of approximately 700 nM (Figure 2C).
We evaluated the kinetics of this decrease by measuring HOXA9
and MEIS1 mRNA levels over time in cells treated with 3 mM
EPZ004777 (Figure 2D). Levels of both transcripts were signifi-
cantly decreased within 48 hr of compound addition, and were
maximally reduced after 6–8 days of EPZ004777 treatment
(fitting of these data yielded estimated half-lives of 2.3 and
3.3 days for HOXA9 and MEIS1 inhibition, respectively). This
decrease was not due to a general inhibitory effect on gene
expression since transcript levels of the housekeeping gene
TBP were unaffected (Figure 2D).
EPZ004777 Selectively Inhibits Proliferation
of MLL-Rearranged Cells
Having established that EPZ004777 can inhibit H3K79 methyla-
tion and block MLL fusion target gene expression, we investi-
gated whether this translated into antiproliferative activity in
MLL-rearranged leukemic cells. We performed proliferation
assays over several days with MV4-11 and MOLM-13 cells in
the presence or absence of 3 mM EPZ004777. Jurkat cells
were included as a non-MLL-rearranged cell line control. As
shown in Figure 3A, the effect of extended EPZ004777 treatment
was remarkably specific for the MLL-rearranged cell lines. The
number of viable MV4-11 and MOLM-13 cells was dramatically
reduced by EPZ004777, whereas the growth of Jurkat cells
was unaffected. A small population of MV4-11 cells remained
viable in the presence of EPZ004777, but their number remained
constant when growth curves were tracked over longer periods
indicating that they had ceased to divide (see Figure S1 available
online). The lack of effect on Jurkat cells was not due to differ-
ences in the ability of EPZ004777 to inhibit DOT1L in these cells
as measured by immunoblot for cellular H3K79me2 levels (Fig-
ure 2A, upper panel). This analysis also revealed a significant
delay before the antiproliferative effects of EPZ004777 became
apparent; bothMLL-rearranged cell lines continued to proliferate
at a normal rate for several days after exposure to the inhibitor.
This may reflect the time required to reverse fully the aberrant
expression of MLL fusion target genes following DOT1L inhibi-
tion, a process that presumably involves depletion of methylated
H3K79, followed by decreased mRNA expression and reduced
levels of gene products critical for leukemogenic growth. To
expand our analysis of the differential sensitivity of MLL-rear-
ranged cell lines to EPZ004777, we determined IC50 values for
inhibition of proliferation in a panel of six MLL-rearranged and
six nonrearranged human leukemia cell lines. The MLL-rear-
ranged panel (Table 2) included human cell lines derived from
ALL, AML and biphenotypic leukemias harboring MLL-AF4,
MLL-AF9, orMLL-ENL fusions. As shown in Figure 3B, and TableCancer Cell 20, 53–65, July 12, 2011 ª2011 Elsevier Inc. 55
Figure 2. EPZ004777 Inhibits Cellular H3K79 Methylation and MLL Fusion Target Gene Expression
(A) Upper panel: immunoblot analysis of H3K79me2 levels in MV4-11 (MLL-AF4), MOLM-13 (MLL-AF9), and Jurkat human leukemia cell lines following 4 days of
treatment with EPZ004777 at indicated concentrations. Lower panel: time course of depletion of cellular H3K79me2 levels in MV4-11 cells treated with 3 mM
EPZ004777.
(B) Immunoblot analysis of histones extracted from MV4-11 cells treated with 10 mM EPZ004777 with a panel of methyl-lysine and methyl-arginine residue
specific antibodies.
(C) Quantitative real-time PCR analysis of HOXA9 andMEIS1mRNA levels in MV4-11 and MOLM-13 cells following 6 day incubation with EPZ004777. Relative
mRNA expression levels are plotted as a percentage of those in vehicle-treated control cells.
(D) Time course of HOXA9,MEIS1 and TBP mRNA expression in MV4-11 and MOLM-13 cells over 8 days of incubation with 3 mM EPZ004777 as measured by
quantitative real-time PCR. Relative mRNA expression levels are plotted as a percentage of those at day 0. Error bars: standard deviation (SD).
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lar to low micromolar range, whereas IC50s for non-MLL-rear-
ranged cell lines were always above 10 mM or undetermined
due to lack of inhibition at the highest concentration tested
(reported as IC50 > 50 mM in Table 2 and represented as 50 mM
for illustrative purposes in Figure 3B). Concentrations above
50 mMwere not tested because they are above the solubility limit
for EPZ004777, and because efficient loss of H3K79me2 was
achieved at concentrations below 1 mM (Figure 2A). We next
determined whether these results would extend to primary
murine hematopoietic progenitors transformed by retroviral
expression of anMLL-AF9 fusion protein. As shown in Figure 3C,
the proliferation of MLL-AF9-transformed cells was strongly in-
hibited by EPZ004777 at concentrations of 3 mM or greater. In
contrast, the survival of hematopoietic progenitors transformed
by coexpression of HoxA9 and Meis1a was unaffected by
EPZ004777 at concentrations of up to 30 mM. Immunoblot anal-
ysis of histones using an anti-H3K79me2 antibody confirmed
that EPZ004777 inhibited H3K79 methylation in both trans-
formed cell populations (Figure 3D).
These results demonstrate that DOT1L methyltransferase
activity is required for proliferation of MLL-rearranged cells and
MLL fusion-mediated transformation, but is not essential for
proliferation and viability of non-MLL-rearranged cells in culture.56 Cancer Cell 20, 53–65, July 12, 2011 ª2011 Elsevier Inc.EPZ004777 Causes Differentiation and Apoptosis
in MLL-Rearranged Cells
To explore the mechanism of cell killing in more detail, we deter-
mined effects of EPZ004777 on the cell cycle and apoptosis in
MV4-11 and MOLM-13 cells by flow cytometry for DNA content
and Annexin V staining. The results are represented graphically
in Figures 4A and 4B. In MV4-11 cells, a modest increase in
G0/G1 phase, and a decrease in S-phase cells were apparent
after 4 days of incubation with 3 mM EPZ004777. This was fol-
lowed by an increase in sub-G1 and Annexin-positive cells
over the next 6 days, consistent with apoptotic cell death (Fig-
ure 4A). Compound treatment also led to caspase activation
(Figure S2) providing further evidence for an apoptotic compo-
nent to EPZ004777-mediated cell killing. Similar results were
obtained in MOLM-13 cells, although the percentage of
Annexin-positive cells was significantly lower (Figure 4B). We
next analyzed whether EPZ004777 induced differentiation prior
to cell death. MOLM-13 cells were treated with 3 mM
EPZ004777 and monitored for cell surface expression of the
myeloid differentiation marker CD14 by flow cytometry. As
shown in Figure 4C, expression of CD14 was induced following
12 days of EPZ004777 treatment. Gene set enrichment analysis
(GSEA) (Subramanian et al., 2005) of genes upregulated by
EPZ004777 treatment of MOLM-13 cells (see below) also
Pr
Figure 3. EPZ004777 Selectively Inhibits Proliferation ofMLL-Rearranged Cell Lines andMLL-AF9-TransformedMurine Hematopoietic Cells
(A) Growth of MV4-11 (MLL-AF4),MOLM-13 (MLL-AF9), and Jurkat (non-MLL-rearranged) cells during several days incubation with 3 mMEPZ004777. Viable cells
were counted every 3 to 4 days in the presence of EPZ004777 (+) or DMSO vehicle control () and results plotted on a logarithmic scale. See also Figure S1. Error
bars represent standard deviation.
(B) Effect of EPZ004777 on the proliferation of leukemia cell lines bearing MLL-AF4, MLL-AF9, and MLL-ENL fusions, or cell lines lacking an MLL rearrangement.
Cell lines were maintained in the presence of increasing concentrations of EPZ004777 up to 50 mM. Viable cells counts were used to derive IC50 values after
14 days of treatment for all cell lines apart from THP-1 cells, whichwere treated for 18 days. Fifty percent inhibition of growth was not achieved in HL60, Jurkat and
U937 cells even at the highest EPZ004777 concentration and so IC50 values are given as >50 mM.
(C) Effect of EPZ004777 on the proliferation of primary murine hematopoietic progenitors transformed by retroviral expression of MLL-AF9, or coexpression
of HoxA9 and Meis1a. Retrovirally transformed cells were maintained in the presence of increasing concentrations of EPZ004777 up to 30 mM for 10 days,
then plated in 96-well plates for MTT assay at day 12. Following the MTT assay, plate ODs were read at 570 nM and plotted on the y axis. Results from two
independent transductions are shown for each retroviral construct. Error bars represent standard deviation.
(D) Inhibition of cellular H3K79me2 levels in MLL-AF9 or Hoxa9-Meis1a transformed hematopoietic progenitors following 10 days of treatment with the indicated
concentrations of EPZ004777 as measured by immunoblot analysis of extracted histones with an anti-H3K79me2 antibody.
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lineage markers, including CD14, (normalized enrichment score
[NES] = 1.78, false discovery rate [FDR] = 0.054) (Figure 4D). This
provides further evidence that small-molecule inhibition of
DOT1L promotes some degree of differentiation prior to cell
killing.
EPZ004777 Reverses the MLL-Rearranged Gene
Signature
To determine effects of EPZ004777 treatment on gene expres-
sion in MLL-rearranged leukemia cell lines, RNA was isolated
from MV4-11 cells and MOLM-13 cells treated with 3 mM
EPZ004777 for up to 6 days, amplified, and hybridized to Affy-
metrix microarrays. Statistically significant changes in gene
expression (probes with statistically significant changes (q <
0.15) and up or downregulated at least 2-fold; see Experimental
Procedures) were not observed until 4 days after inhibitor treat-
ment, consistent with the relatively delayed effects ofEPZ004777 on H3K79 methylation and proliferation (Figure 5A).
Among the genes downregulated in MV4-11 andMOLM-13 cells
following 6 days of EPZ004777 treatment are several that have
been previously implicated in MLL fusion-mediated leukemo-
genesis including multiple HOXA genes, MEIS1 and MEF2C
(Figures 5B–5E). GSEA of genes downregulated following
6 day EPZ004777 treatment of MOLM-13 cells demonstrated
strong enrichment (NES = 1.74, FDR = 0.014) for genes over-
expressed in MLL-rearranged human acute leukemias as
compared with MLL-germline acute leukemias (Ross et al.,
2004) (Figure 5B). This indicates that small-molecule inhibition
of DOT1L is able to reverse theMLL-rearranged gene expression
signature in MLL-rearranged cell lines. We next used GSEA to
compare genes downregulated following 6 day EPZ004777
treatment of MOLM-13 (MLL-AF9) or MV4-11 (MLL-AF4) cells
with genes identified as direct targets of MLL-AF9 (see Experi-
mental Procedures and paper by Bernt et al., 2011 [this issue
of Cancer Cell]), or MLL-AF4 (Guenther et al., 2008) throughCancer Cell 20, 53–65, July 12, 2011 ª2011 Elsevier Inc. 57
Table 2. Concentration-Dependent Inhibition of Cell
Proliferation by EPZ004777 in Various Cell Types
MLL Gene Fusion Cell Type IC50 (mM)
a
95% Confidence
Interval for IC50 (mM)
MLL-AF4 RS4;11 6.47 4.22–9.94
MLL-AF4 SEM 1.72 1.21–2.46
MLL-AF4 MV4-11 0.17 0.15–.19
MLL-AF9 THP-1 3.36 2.51–3.80
MLL-AF9 MOLM-13 0.72 0.65–0.80
MLL-ENL KOPN-8 0.62 0.49–0.79
Nonrearranged REH 13.90 8.25–23.46
Nonrearranged Kasumi-1 32.99 30.03–36.24
Nonrearranged 697 36.57 34.77–38.46
Nonrearranged HL-60 >50 NA
Nonrearranged Jurkat >50 NA
Nonrearranged U937 >50 NA
a IC50 is the concentration of compound that results in a half-maximal
degree of inhibition.
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large scale sequencing (ChIP-seq). Genes downregulated by
EPZ004777 in MOLM-13 cells were significantly enriched for
direct MLL-AF9 targets (NES = 1.86, FDR: 0.007, Figure 5C),
whereas genes downregulated by EPZ004777 in MV4-11 cells
were enriched for direct MLL-AF4 targets (NES = 1.51,
FDR: 0.081, Figure 5D). Both results indicate that small-molecule
inhibition of DOT1L decreases the expression of direct MLL
fusion targets. Finally, we compared gene expression changes
caused by EPZ004777 treatment of MOLM-13 (MLL-AF9) cells
with those caused by genetic knockout of Dot1l in a mouse
model of MLL-AF9 leukemia (see Experimental Procedures
and paper by Bernt et al., 2011 [this issue of Cancer Cell]). We
found significant overlap between these gene expression
changes (NES = 1.58, FDR: 0.024, Figure 5E) indicating that
EPZ004777 treatment and genetic ablation of Dot1l cause cell
killing of MLL-rearranged cells through similar pathways.In Vivo Efficacy of EPZ004777 in a Mouse Xenograft
Model of MLL
We next tested the efficacy of EPZ004777 in a mouse xenograft
model of MLL. As a first step, we determined whether
EPZ004777 was capable of inhibiting DOT1L activity in vivo.
We chose to do this in a mouseMV4-11 subcutaneous xenograft
model, since tumor tissue can be readily harvested and as-
sessed for changes in H3K79 methylation levels. The poor phar-
macokinetic properties of EPZ004777 precluded conventional
dosing methods. Instead, compound was delivered via subcuta-
neously implanted mini-osmotic pumps capable of continuous
infusion for a period of 7 days. Six female nude mice bearing
MV4-11 xenograft tumors of sizes ranging from 300 to
400 mm3 were implanted with pumps loaded with a 50 mg/ml
solution of EPZ004777. A control group of five tumor bearing
mice did not receive pumps. After 6 days, all mice were sacri-
ficed and tumors were harvested. Immunoblot analysis of
histones extracted from MV4-11 tumors revealed that
H3K79me2 levels were significantly decreased in tumors from58 Cancer Cell 20, 53–65, July 12, 2011 ª2011 Elsevier Inc.mice treated with EPZ004777 relative to untreated controls (Fig-
ure 6A). Analysis of plasma samples taken during this experiment
revealed that treated mice were exposed to average circulating
levels of 0.55 ± 0.12 mM EPZ004777.
Having demonstrated that EPZ004777 is able to inhibit
DOT1L in vivo, we next tested the efficacy of EPZ004777 in
a more therapeutically relevant model of MLL in which MV4-
11 cells are injected into the tail vein of immunodeficient mice
resulting in disseminated leukemic disease. Female NSG mice
were injected via tail vein with 1 3 106 MV4-11 cells stably ex-
pressing the firefly luciferase gene. Leukemia engraftment was
confirmed by bioluminescence imaging 5 days after inoculation,
at which point animals were divided into treatment and control
groups (n = 8 per group). Optimization of EPZ004777 formula-
tion enabled us to increase solubility to 150 mg/ml. Mice were
therefore implanted with pumps loaded with vehicle alone, or
containing EPZ004777 at concentrations of 50, 100, or
150 mg/ml. Pilot experiments indicated that mini-pumps con-
taining 100 and 150 mg/ml EPZ004777 solutions could maintain
average steady-state plasma concentrations of 0.64 ± 0.48 and
0.84 ± 0.45 mM, respectively. Osmotic pumps were replaced
once to achieve a total of 14 days of in vivo compound expo-
sure (from day 5 to day 19 postinoculum, see Figure 6B). Local
irritation at the pump implant site in the 100 and 150 mg/ml
groups precluded a second pump replacement (see Experi-
mental Procedures). Despite the limited 14 day duration of
EPZ004777 exposure achieved, we observed a dose-depen-
dent and statistically significant increase in median survival
(p = 0.0002, 0.0007 and 0.0285 for the 150, 100, and 50 mg/ml
dose groups, respectively, log-rank test, Figure 6B). Histo-
pathological analysis of similarly xenografted mice confirmed
that animals were dying of leukemic disease (data not shown).
EPZ004777 administration was well tolerated, and no signifi-
cant weight loss was observed (Figure S3). Together, these
results demonstrate that EPZ004777 has both pharmacody-
namic and antitumor efficacy in a mouse xenograft model of
MLL leukemia.
Efficacious Doses of EPZ004777 Are Well Tolerated
in Normal Mice
To further explore whether a therapeutic window for small-mole-
cule DOT1L inhibition exists, we treated normal C57BL/6 mice
with mini-pumps loaded with vehicle or 150 mg/ml EPZ004777
for 14 days and monitored for signs of toxicity. We focused on
effects on the hematopoietic system, in particular, because
DOT1L has been shown to play a role in normal hematopoietic
development and homeostasis. As in the previous experiments,
EPZ004777 was well tolerated and no overt toxicity was
observed. Complete blood count analysis after 14 days of
continuous exposure to EPZ004777 revealed a statistically
significant increase in the total white blood cell count, which re-
sulted from an increase in neutrophils, monocytes, and lympho-
cytes (Figure 6C). The etiology of this effect is not clear. We did
not find any significant differences in the colony forming potential
of bone marrow progenitors after 14 days of in vivo exposure
(Figure 6D), and bone marrow cellularity was preserved (Fig-
ure S4A). Further analysis of more primitive hematopoietic
compartments revealed a statistically significant decrease in
committed progenitors (LinSca1c-Kit+), that was most
Figure 4. EPZ004777 Causes Apoptosis and Differentiation in MLL-Rearranged Cell Lines
(A and B) MV4-11 (A) and MOLM-13 (B) cells were treated with 3 mMEPZ004777 for up to 10 days and analyzed by flow cytometry every 2 days for DNA content,
and Annexin V staining. See also Figure S2.
(C) MOLM-13 cells were incubated in the presence of 3 mM EPZ004777 for 12 days and analyzed by flow cytometry for cell surface expression of CD14. Similar
results were obtained in two independent experiments.
(D) Gene Set Enrichment Analysis (GSEA) (Subramanian et al., 2005) of genes upregulated by EPZ004777 treatment of MOLM-13 cells as compared with
members of the KEGG hematopoietic cell lineage gene set. The heat map shows genes comprising the leading edge of the GSEA plot. Red indicates high
expression; blue indicates low expression.
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LinSca1c-Kit+CD34+FcgRII/IIIlo) and megakaryocyte/
erythroid progenitors (MEP, Il-7RLinSca1c-Kit+CD34
FcgRII/III). Granulocyte/monocyte progenitors (GMP, Il-7R
LinSca1c-Kit+CD34+FcgRII/III+) were not significantly
affected (Figures S4B and S4C). Similarly, flow cytometric anal-
ysis of populations that are highly enriched for hematopoietic
stem cells (LinSca1+c-Kit+ = LSK; long-term repopulating
cells defined as LinSca-1+cKit+CD34flk2; and LinSca-1
+
c-Kit+CD34flk2CD48CD150+) did not reveal any difference
betweenmice treated with EPZ004777 and control mice (Figures
S4B and S4C). These results demonstrate that it is possible to
achieve a therapeutically meaningful level of small-molecule
DOT1L inhibition, without overt toxicity or severe hematopoietic
side effects.
DISCUSSION
The small-molecule inhibitor EPZ004777 provides a powerful
tool for understanding the biological role of DOT1L enzymatic
activity. As we demonstrate here, this compound is an extremely
potent and selective inhibitor of its target enzyme, thus providing
sufficient pharmacologic specificity with which to probe the
cellular consequences of DOT1L inhibition in MLL-transformed
and nontransformed cells. We find that inhibition of DOT1L by
EPZ004777 results in robust and selective ablation of cellular
H3K79methylation, which, in turn, leads to diminished transcrip-
tion of key genes associated with leukemogenesis in MLL
disease, such as HOXA9 and MEIS1. Strikingly, the inhibitionof DOT1L-catalyzed H3K79 methylation is cytotoxic to leukemic
cells bearing theMLL translocation, but has little effect on prolif-
eration of nontranslocated cells. A particularly powerful demon-
stration of this selectivity is the finding that hematopoietic
progenitors transformed by MLL-AF9 expression are sensitive
to EPZ004777 treatment, whereas those transformed by
HoxA9 and Meis1, a combination that presumably bypasses
the requirement for DOT1L activity, are not.
Killing of MLL-translocated cells by EPZ004777 involves an
apoptotic component and is preceded by phenotypic and
gene expression changes that suggest attempted hematopoietic
differentiation. Gene expression analysis of inhibitor treated
MLL-rearranged cells demonstrates a reversal of an MLL-rear-
ranged gene signature, previously derived through transcrip-
tomic analysis of primary human acute leukemia samples
(Ross et al., 2004). This includes downregulation of genes known
to be critical for MLL fusion-mediated leukemogenesis such as
members of the HOXA gene cluster and MEIS1 (Ayton and
Cleary, 2003; Faber et al., 2009; Kumar et al., 2009; Wong
et al., 2007; Zeisig et al., 2004). These data are concordant
with results seen for DOT1L message ablation using genetic
knockdown methodologies, a manipulation that inhibits MLL
fusion-driven tumor progression in vitro and in vivo as detailed
in the paper by Bernt et al. (2011) (this issue of Cancer Cell).
Indeed, our gene profiling results demonstrate overlapping tran-
scriptomic impact of both methods of DOT1L inhibition.
In vivo administration of EPZ004777 results in an extension of
survival in amouse xenograft model of MLL. Although this exten-
sion in survival is significant, its duration is relatively modest.Cancer Cell 20, 53–65, July 12, 2011 ª2011 Elsevier Inc. 59
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Figure 5. Effect of EPZ004777 Treatment on MLL-Rearranged Gene Expression
(A) Gene expression changes following treatment of MV4-11 cells with EPZ004777 for 2, 4, or 6 days and MOLM-13 cells for 6 days. Two-group comparison
expression data were collapsed to unique gene symbols. Changes in gene expression were filtered by log2 change > 1 or < 1 and by false discovery rate
q values < 0.15.
(B) GSEA of genes downregulated by EPZ004777 treatment of MOLM-13 cells as compared with genes overexpressed in MLL-rearranged human acute
leukemias (Ross et al., 2004). The heat map shows genes comprising the leading edge of the GSEA plot. Red indicates high expression; blue indicates low
expression.
(C) GSEA of genes downregulated by EPZ004777 treatment of MOLM-13 cells as compared with genes bound by MLL-AF9 in MLL-AF9-transformed murine
hematopoietic progenitors (see Experimental Procedures and Bernt et al., 2011 [this issue of Cancer Cell]). The heat map shows genes comprising the leading
edge of the GSEA plot.
(D) GSEA of genes downregulated by EPZ004777 treatment of MV4-11 cells as compared with genes bound by MLL-AF4 in human SEM cells (Guenther et al.,
2008). The heat map shows genes comprising the leading edge of the GSEA plot.
(E) GSEA of genes downregulated by EPZ004777 treatment of MOLM-13 cells as compared with genes downregulated following genetic knockout of Dot1l in
a murine MLL-AF9 leukemia model (see Experimental Procedures and Bernt et al., 2011 [this issue of Cancer Cell]). The heat map shows genes comprising the
leading edge of the GSEA plot.
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experiment, suboptimal circulating levels of EPZ004777, or
a combination of both factors. For example, while the circulating
levels of EPZ004777 are well above IC50 values for inhibition of
proliferation of cultured MV4-11 cells, factors such as plasma
protein binding may limit the effective free fraction of
EPZ004777 available for DOT1L inhibition in tumor cells. In
normal mice, therapeutically active doses of EPZ004777 do
not give rise to overt toxicity. Careful hematologic analysis
reveals a mild to moderate decrease in myeloid progenitor
compartments. This did not translate into a significant decrease
in peripheral blood counts over the 2week dosing period, but rai-
ses the possibility that extended courses of treatment with
a DOT1L inhibitor could affect normal hematopoiesis. Overall,60 Cancer Cell 20, 53–65, July 12, 2011 ª2011 Elsevier Inc.however, the absence of severe hematopoietic side effects
with EPZ004777 is encouraging.
The present paper and the paper by Bernt et al. (2011) (this
issue of Cancer Cell) demonstrate clearly that ablation of
DOT1L enzymatic activity, either by genetic knockdown of the
entire protein or blockade of the catalytic active site, selectively
kills cells bearing the MLL translocation in culture and has anti-
tumor activity in in vivo models of MLL. The effect of DOT1L inhi-
bition by EPZ004777 in cell culture and in a mouse xenograft
model of disease provides strong support for the use of
DOT1L selective inhibitors as amolecular basis for targeted ther-
apeutics against MLL-rearranged leukemias. Furthermore, the
selectivity for MLL-rearranged cells in culture, and our ability to
demonstrate efficacy in a mouse model of MLL at doses that
Figure 6. In Vivo Activity of EPZ004777
(A) H3K79me2 levels were evaluated by immunoblot in subcutaneous MV4-11 tumors derived from untreated animals or animals implanted with pumps con-
taining a 50 mg/ml solution of EPZ004777 for a period of 6 days.
(B) EPZ004777 extends survival of NSG mice after intravenous injection of MV4-11 cells. MV4-11 cells were injected into the tail vein of NSG mice, and animals
were implanted with pumps containing vehicle or 50, 100, or 150 mg/ml EPZ004777. Pumps were exchanged once to give a total of 14 days of exposure as
indicated. See also Figure S3A.
(C) Complete blood count analysis in C57BL/6 mice treated for 14 days with EPZ004777 or vehicle control. WBC, white blood cell count; NE, neutrophils; LY,
lymphocytes; MO, monocytes; Hb, Hemoglobin; Plt, platelets; K/ml, thousands per microliter; M/ml, millions per microliter. N = 5 mice per group, *p < 0.01, all
others not significant (p > 0.05).
(D) Effect of 14 days of EPZ004777 treatment on colony formation of hematopoietic progenitors. Fivemice per group, all differences not significant (p > 0.05). Error
bars represent standard error of the mean. See also Figures S3B–S3D.
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on inhibition of DOT1L, may demonstrate an exploitable thera-
peutic index.
In summary, we have designed and characterized a potent,
selective DOT1L inhibitor as a starting point toward the develop-
ment of personalized medicines for the treatment of patients
suffering from MLL. The poor pharmacokinetic properties of
EPZ004777 preclude its clinical development; however, we are
currently developing related inhibitors with improved potency
and drug-like properties for this purpose. The data presented
here demonstrate the utility of DOT1L inhibition as an approach
to targeted therapy for this disease. In a broader context, the
current results also provide validation for small-molecule inhibi-
tion of HMTs as a therapeutic modality in cancer and other
diseases where genetic alterations to these epigenetic enzymes
drive pathogenesis. Continued research into pharmacologically
tractable mechanisms of HMT inhibition should yield novel medi-
cines for patients suffering from such diseases.
EXPERIMENTAL PROCEDURES
EPZ004777
EPZ004777 was synthesized by Epizyme. Stock solutions (50 or 10 mM)
were prepared in DMSO and stored at 20C. Serial dilutions of stocksolutions were carried out just prior to use in each experiment and final
DMSO concentrations were kept at, or below 0.2%. For experiments
involving RS4;11 and Kasumi-1 cells, stock solutions were prepared in
water.
Determination of Inhibitor IC50 Values
Preparation of recombinant purified human DOT1L protein is described in
Supplemental Experimental Procedures. Avian (chicken) erythrocyte oligonu-
cleosomes were purified as previously described (Fang et al., 2004).
EPZ004777 was serially diluted 3-fold in DMSO for a total of ten concentra-
tions, beginning at 1 mM. A 1 ml aliquot of each inhibitor dilution was plated
in a 384-well microtiter plate. The100% inhibition control consisted of
2.5 mM final concentration of the product inhibitor S-adenosyl-L-homocys-
teine, (SAH). Compound was incubated for 30 min with 40 ml per well of
0.25 nM DOT1L(1-416) in assay buffer (20 mM TRIS [pH 8.0] 10 mM NaCl,
0.002% Tween 20, 0.005% Bovine Skin Gelatin, 100 mM KCl, and 0.5 mM
DTT). 10 ml per well of substrate mix comprising assay buffer with 200 nM
3H-SAM (American Radiolabeled Chemicals: 80 Ci/mmol), 600 nM unlabeled
SAM, and 20 nM nucleosomes were added to initiate the reaction (both
substrates were present in the final reaction mixture at their respective KM
values, an assay format referred to as ‘‘balanced conditions’’ (Copeland,
2003). Reactions were incubated for 120 min and quenched with 10 ml per
well of 800 mM SAM. Incorporation of radioactivity into nucleosome substrate
was measured in a flashplate similar to previously described studies (Sneer-
inger et al., 2010). IC50 values for enzymes in the histone methyltransferase
panel were determined under similar balanced assay conditions with both
SAM and protein/peptide substrate present at concentrations equal to theirCancer Cell 20, 53–65, July 12, 2011 ª2011 Elsevier Inc. 61
Cancer Cell
A DOT1L Inhibitor Kills MLL Leukemia Cellsrespective KM values. See Supplemental Experimental Procedures for more
information.
Determination of SAM Competition
Experimental conditions were similar to IC50 experiment with the following
exceptions. EPZ004777 was serially diluted 2-fold in DMSO for a total of ten
concentrations, beginning at 10 nM. SAM was titrated over a range between
250 and 8000 nM . To monitor the reaction, a radioactive tracer 3H-SAM
was used in each reaction, equivalent to 200 nM (which was accounted for
in the total SAM concentration). Each SAM concentration had equivalent wells
with no enzyme present in the reaction as negative controls. Reactions were
incubated for 120 min and quenched with 10 ml per well of 800 mM SAM.
Cell Culture
Human leukemia cell lines MV4-11 (CRL-9591), THP-1 (TIB-202), RS4;11
(CRL-1873), Kasumi-1 (CRL-2724), HL-60 (CCL-240), REH (CRL-8286), and
Jurkat (TIB-152) were obtained from the ATCC. SEM (ACC 546), KOPN-8
(ACC 552), 697 (ACC 42), and MOLM-13 (ACC 554) cells were obtained from
DSMZ. All cell culture reagents were purchased from Invitrogen Life Technol-
ogies and cells were maintained in a humidified incubator set to 37C, 5%
CO2. RS4;11, Kasumi-1, MOLM-13, KOPN-8, REH, 697, and Jurkat cells
were grown in RPMI with 10% FBS. THP-1 cells were grown in RPMI plus
10% FBS supplemented with 13 b-mercaptoethanol. MV4-11, SEM, and
HL-60 cell lines were grown in IMDM with 10% FBS.
Generation of MLL-AF9- and HoxA9-Meis1a-Transformed Murine
Hematopoietic Progenitors
Mouse fetal liver cells were transduced with MSCV-based MLL-AF9-IRES-
GFP or Hoxa9-IRES-GFP and Meis1a-Puromycin retroviral vectors and prop-
agated as described in Supplemental Experimental Procedures.
Analysis of Cell Proliferation and Viability
For assessment of cell proliferation and viability in human cell lines, exponen-
tially growing cells were plated, in triplicate, in 96-well plates at a density of 33
104 cells/well in a final volume of 150 ml. Cells were incubated in the presence
of 3 mM (proliferation curve), or increasing concentrations (IC50 determination)
of EPZ004777 up to 50 mM. Viable cell number was determined every 3–4 days
for up to 18 days using the Guava Viacount assay (Millipore # 4000-0040) and
analyzed on a Guava EasyCyte Plus instrument (Millipore) according to the
manufacturer’s protocol. On days of cell counts, growth media and
EPZ004777 were replaced and cells split back to a density of 5 3 104 cells/
well. Total cell number is expressed as split-adjusted viable cells per well.
For each cell line, IC50 values were determined from concentration-depen-
dence curves at each time point using Graphpad Prism software. Experiments
to determine IC50 values continued until IC50 values stabilized (day 18 for
THP-1 cells, day 14 for all other cell lines).
For assessment of the effect of EPZ004777 treatment on transformed
murine hematopoietic progenitors, cells from two independent transductions
for each virus were plated in 24-well plates at a density of 0.5–1 3 105 cell/
well in 1 ml media in 24-well plates and exposed to increasing concentrations
of EPZ004777 up to 30 mM. Cells were counted and replated at equal cell
numbers in freshmedia with fresh compound every 3–4 days. For MTT assays,
cells from serial replatings were harvested on day 10 and plated, in triplicate at
2 3 104 cells/well in 100 ml media with the appropriate concentration of
EPZ004777. Cells were incubated for 2.5 days, the exposed to 10 ml MTT-
reagent for 3 hr, and lysed over night in 100 ml MTT- solubilization buffer
(both from Cell Proliferation Kit I [MTT], Roche Diagnostics, Indianapolis, IN).
Western Blot Analysis
For western blot analysis in human cell lines, exponentially growing cells were
plated in 12-well plates at 23 105 cells/well in a final volume of 2 ml. Cells were
incubated in the presence of 3 mM (time course analysis), or increasing
concentrations (IC50 determination) of EPZ004777 up to 12.5 mM. Cells
(1–23 106) were harvested at the appropriate time point and histones were ex-
tracted as detailed in Supplemental Experimental Procedures. Histones
(400 ng) were separated on 4%–20%Tris-Glycine gels (Invitrogen), transferred
to 0.2 mM nitrocellulose membranes and probed with the appropriate primary
antibodies (see Supplemental Experimental Procedures for a list of primary62 Cancer Cell 20, 53–65, July 12, 2011 ª2011 Elsevier Inc.antibodies used) in Li-COROdyssey blocking buffer (Li-Cor 927-40000) diluted
1:3 with water. Following primary antibody incubation, membranes were
probed with IRDye 800CW Donkey-anti-mouse IgG (Li-COR 926-32212) or
Alexa Fluor 680 goat anti-rabbit IgG (Invitrogen A-21076) secondary anti-
bodies and signal was detected using the Li-COR Odyssey Infrared system.
For western blot analysis of subcutaneous MV4-11 xenograft tumors,
tumors were harvested and snap-frozen in liquid nitrogen. Frozen tumor
samples were cut into a 20 mg pieces and placed in 500 mL of ice cold lysis
buffer (see Supplemental Experimental Procedures). A single 5 mm stainless
steel bead (QIAGEN 69989) was added to each tube and samples homoge-
nized using the TissueLyser II (QIAGEN 85210). Samples were homogenized
by high speed shaking for 60 s at a frequency of 30 times/second. Histones
were extracted and analyzed by immunoblotting as described above.
For western blot analysis in transformed murine hematopoietic progenitors,
cells were incubated in the presence of increasing concentrations of
EPZ004777 up to 30 mM for 10 days. Cells were counted and replated at equal
cell numbers in fresh media with fresh compound every 3–4 days. Histones
were extracted and analyzed by immunoblotting as detailed in Supplemental
Experimental Procedures.
Quantitative Real-Time PCR
Exponentially growingMV4-11 andMOLM-13 cells were plated, in triplicate, in
96-well plates at 33 104 cells/well in a final volume of 150 ml. Cells were incu-
bated in the presence of 3 mM (time course analysis), or increasing concentra-
tions (IC50 determination) of EPZ004777 up to 12.5 mM. Compound and media
were refreshed every 3–4 days during both the time course and concentration
response experiments. RNA from cells was isolated using the 96-well Prom-
ega RNA isolation kit (Z3505) according to the manufacturer’s protocol.
Approximately 30% of the total RNA isolated was reverse transcribed using
a high capacity cDNA reverse transcription kit (Applied Biosystems
4368813) according to the manufacturer’s protocol. Predesigned labeled
primer and probe sets for HOXA9 (Hs00365956), MEIS1 (Hs00180020), and
TBP (4333769F) were purchased from Applied Biosystems. qPCR reactions
contained 50 ng cDNA, 13 labeled primer and probe set, and 13 Taqman
universal PCR master mix (Applied Biosystems 4304437). Samples were run
on a 7900 HT Fast Real Time PCR machine (Applied Biosystems) with cycling
conditions of 2 min at 50C, 10 min at 95C, 40 cycles at 15 sec at 95C and
1 min at 60C. Target gene cycle numbers were normalized to the house
keeping gene b2-microglobulin to get a DCT value (Applied Biosystems
4333766). Percentage of vehicle-treated control was calculatedwith the Equa-
tion (2^-DDCT)*100where theDDCT is the difference between normalized target
gene and vehicle-treated control (DCT sample – DCT control = DDCT).
Flow Cytometric Analysis of Cell Cycle and Annexin V
Exponentially growing MV4-11 and MOLM-13 cells were plated in 12-well
plates at a density of 2 3 105 cells/ml. Cells were incubated with 3 mM
EPZ004777 in a final volume of 2 mls for up to 10 days. For incubations longer
than 4 days, media and compound were replaced on days 4 and 7 and cells
were split back to a density of 2 3 105 cells/ml. Cells were harvested on
days 0, 2, 4, 6, 8, and 10 and split to allow simultaneous analysis of cell cycle
and Annexin V staining. Apoptosis was determined using the Guava Nexin
Assay (Millipore 4500-0450) and cells prepared according to manufacturer’s
recommendations. Cells treated for cell cycle analysis were pelleted by centri-
fugation at 2003 g for 5 min at 4C. Pellets were washed twice with PBS then
fixed with 70% ethanol on ice for 2 hr. Following fixation cells were washed
once more with PBS and stained with the Guava cell cycle reagent (Millipore
4500-0220) for 20 min. Samples were analyzed using the Guava EasyCyte
Plus System (Millipore).
Analysis of CD14 expression
Exponentially growing MOLM-13 cells were seeded in a 12-well plate at
a density of 2 3 105 cells/ml in the presence of 3 mM EPZ004777 for
12 days. Media and compound were refreshed on days 4 and 8 and cells
were split back to 23 105 cells/ml. Cells (33 105) were pelleted by centrifuga-
tion at 200 cells g and washed twice with PBS. Pellets were resuspended in
200 ml of 4% formaldehyde in PBS and fixed for 10 min at 37C. Fixed cells
were washed twice with blocking buffer (0.5% BSA, in PBS). After the last
wash, cells were blocked with 1 ml of blocking buffer for 10 min at room
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buffer containing either a mouse anti-CD14 labeled with FITC (1:50 dilution
Chemicon CBL453F) ormouse IgG isotype control FITC-labeled (1:50Millipore
AP124F) antibody for 1 hr at room temperature. Cells were pelleted and resus-
pended in 200 ml of PBS and 10,000 events were analyzed using the Express
Pro software on the Guava EasyCyte Plus System (Millipore).
RNA Amplification and Microarray Data Analysis
Exponentially growingMV4-11 andMOLM-13 cells were plated, in triplicate, in
6-well plates at a density of 4 3 105 cells/ml in 3 ml media in the presence or
absence of 3 mMEPZ004777 for 2, 4, or 6 days. Cells were split back to 23 105
cells/ml and medium and compound were refreshed on day 4. Cells were pel-
leted by centrifugation at 2003 g, washed twice in PBS, snap-frozen on liquid
nitrogen, and shipped to Expression Analysis, Inc. (Durham, NC) for RNA prep-
aration and transcriptional profiling (see Supplemental Experimental Proce-
dures). To determine whether genes targeted by MLL fusion proteins, or over-
expressed in MLL-rearranged leukemias were suppressed by EPZ004777
treatment, Gene Set Enrichment Analysis (http://www.broadinstitute.org/
gsea/index.jsp) was performed on control versus EPZ004777-treated expres-
sion files for each time point and cell line tested. The transcript lists used in this
analysis were as follows. (1) MLL-AF9 targets –a list of 139mouse genes deter-
mined to be direct targets of the MLL-AF9 fusion protein by ChiP-seq in MLL-
AF9-transformed hematopoietic progenitors (see Bernt et al., 2011 [this issue
of Cancer Cell]). The mouse gene list was mapped to 106 human orthologs
using the NCBI Homologene database. (2) MLL-AF4 targets a list of human
genes determined to be direct targets of the MLL-AF4 fusion protein by
ChIP-seq in SEM cells. Genes were generated from Table S2 (Guenther
et al., 2008) The ‘‘SEM fusion’’ was selected as positive (= 1). A total of 238
fusion targets were collapsed to 168 unique genes. (3) A common expression
signature for MLL-rearranged acute leukemias, irrespective of lineage, (Ross
et al., 2004) was generated from Table S13. The top 100 probes were used,
excluding seven genes whose expression in leukemia with MLL fusion was
below those in leukemia without the fusion. Ninety-three probe sets were
collapsed into 73 unique genes. (4) Genes downregulated in in vivo established
murine MLL-AF9 leukemia cells 5 days after deletion of Dot1l. Probes were
selected by p value < 0.01 and fold change < 2 (see Bernt et al., 2011 [this
issue of Cancer Cell]). A total of 70 mouse transcripts were mapped to 50
human orthologs.
The target lists were manually combined with MSigDB version 3, C2 KEGG
gene set (http://www.broadinstitute.org/gsea/msigdb/index.jsp) as back-
ground. C2 KEGG was also used for assessment of enrichment of KEGG
hematopoietic lineage genes. Due to small sample sizes, permutations by
gene sets rather than by phenotypes were conducted to assess statistical
significance of the gene set enrichment.
For determination of statistically significant changes in gene expression
among each two-group comparison (EPZ004777 versus control), probe sets
were collapsed to unique genes (by maximum probe signal). False discovery
rate or q valueswere calculated based on t test p values, using qvalue package
from R / Bioconductor (http://www.bioconductor.org/). Changes in gene
expression were filtered for log2 difference > 1 or < 1 and q values < 0.15.
Pharmacokinetics
Blood samples were collected and EPZ004777 concentrations in plasma
determined by an internal standard liquid chromatography tandem mass
spectrometry method using protein precipitation and calibration standards
prepared in blank mouse plasma. Reported concentrations are averaged
from six mice in the 50 mg/ml mini-osmotic pump s.c. MV4-11 xenograft
experiment, and five mice each in 100 and 150 mg/ml mini-pump pilot PK
experiments.
MV4-11 Tumor Models
Animal experiments were performed at the Animal Research Facilities at Chil-
dren’s Hospital Boston, the Dana-Farber Cancer Institute Boston, or the Pied-
mont Research Center North Carolina. Animal studies were approved by the
Children’s Hospital, Piedmont or Dana-Farber Cancer Institute Animal Care
and Use Committees. Experiments involving the subcutaneous MV4-11
xenograft model were performed at Piedmont Research Center (NC). Nine-
week-old female nude mice (nu/nu, Harlan Laboratories, US) were injectedsubcutaneously with MV4-11 cells in the right flank (200 ml of a 5 3 107
cells/ml suspension in a 1:1 mixture of PBS and Matrigel (BD Biosciences)).
Mice were randomized to treatment groups when tumor sizes reached 300–
400 mm3. Six mice received subcutaneous implant of osmotic pumps (Alzet
Model 2001, Durect Corp., Cupertino, CA), containing 50 mg/ml EPZ004777
in 10% ethanol, 90% water, and five control mice received no pump implant.
Six days after pump implant, animals were sacrificed and tumor samples from
treated and control animals were collected for immunoblot analysis. For the
disseminated leukemia model, MV4-11 cells were transduced with the
pMMP-LucNeo retrovirus as previously described (Armstrong et al., 2003).
Eight-week-old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were
purchased from Jackson Laboratories (Bar Harbor, ME). A total of 1 3 107
MV4-11-LucNeo cells were injected intravenously via the lateral tail vein.
Engraftment of disseminate leukemia was determined by bioluminescence
imaging (IVIS Spectrum, Caliper Life Sciences, Hopkinton, MA) after injection
of 75 mg/kg of D-luciferin (Promega, Madison, WI), as previously described
(Armstrong et al., 2003). Animals with documented leukemia were divided
into treatment groups consisting of vehicle (15% ethanol, 50% PEG300,
35% water) loaded osmotic pumps, or EPZ004777 at 50, 100, or 150 mg/ml.
Osmotic pumps were replaced after one week. Irritation caused by compound
precipitation was observed in the 100 and 150 mg/ml dose groups, precluding
additional pump replacements. Animals were monitored daily for clinical
symptoms, andwere euthanized when they displayed signs of distress consis-
tent with terminal leukemic disease. Log-rank analysis was used to determine
statistical significance of the survival curves (Prism, GraphPad Software, La
Jolla, CA).
Hematologic Analysis of EPZ004777-Treated Mice
Eight-week-old C57BL/6 mice (Charles River Labs, Wilmington, MA) were im-
planted with osmotic pumps loaded with vehicle or EPZ004777 at 150 mg/ml,
as described above. Osmotic pumpswere replaced on day 7 to give 14 days of
continuous EPZ004777 or vehicle exposure after which animals were eutha-
nized and hematologic organs were collected. Blood for complete blood count
analysis was obtained via cardiac puncture (terminal bleed). Bone marrow cell
suspensions were prepared by crushing bones in a mortar after removal of
muscle and connective tissues. Red blood cells were lysed on ice using red
blood cells lysis buffer Puregene RBC Lysis Solution (Gentra Systems).
Bone marrow lineage staining was performed as described in Supplemental
Experimental Procedures. For colony forming assays, 20,000 nucleated
bonemarrow cells/plate were plated in duplicate inM3434 (StemCell Technol-
ogies, Vancouver, BC, Canada) methylcellulose with 50 U/ml Penicillin/Strep-
tomycin (GIBCO, Invitrogen, Carlsbad, CA). Colonies were scored 8–9 days
after plating.
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